Cargando…

CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies

Dipeptidyl peptidase IV (DPP-IV) inhibitor has been expected to be a new class of anti-diabetic agent. The present study was designed to characterize the pharmacological profiles of CMD-05, a novel DPP-IV inhibitor discovered in our laboratory, in vitro and in vivo. The IC(50) of CMD-05 on DPP-IV in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jie, Li, Huan, Hu, Xiangnan, Yang, Lu, Chen, Qi, Hu, Congli, Chen, Zhihao, Tian, Xiaoyan, Yang, Yang, Luo, Ying, Gan, Run, Yang, Junqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390258/
https://www.ncbi.nlm.nih.gov/pubmed/28406239
http://dx.doi.org/10.1038/srep46628